BMS strikes $14bn deal for Karuna Therapeutics
European Pharmaceutical Review
DECEMBER 22, 2023
The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.
Let's personalize your content